Effect of NNRTI or INSTI on Nonalcoholic Steatosis in HIV/AIDS Patients

Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Apr 10, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different types of HIV medications on a liver condition called nonalcoholic fatty liver disease (NAFLD) in patients living with HIV/AIDS. Specifically, the researchers want to find out if there are any differences in liver fat and scarring between patients who start treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs) and those who start with integrase strand transfer inhibitors (INSTIs). This is important because many people with HIV also have NAFLD, and understanding how different treatments affect this condition can help improve patient care.

To be eligible for the study, participants should be adults who are newly diagnosed or currently receiving treatment for AIDS and can regularly visit the hospital for check-ups. They need to be able to follow the treatment plan and understand the study's details. During the trial, participants will undergo tests to measure liver health and will be monitored over time. Importantly, those with mobility issues or who struggle to follow the treatment plan may not be able to participate. This study offers a chance to contribute to important research that could help improve the health of individuals living with HIV.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newly treated or treated AIDS patients;
• • Regular follow-up visits to the hospital, medication compliance is good;
• • Patients or their family members were willing to participate in the study by understanding the study plan and providing written informed consent.
• Exclusion Criteria:
• • Unable to complete the position requirements of ultrasonic examination (lying flat) due to mobility difficulties;
• • Patients have poor compliance and cannot follow up regularly or take medicine on time;
• • Patients or family members cannot understand the conditions and objectives of the study;
• • Other conditions considered unsuitable for inclusion by the investigator.